Appendix 4E & 2017 Full Year Statutory Accounts
Filed with ASX · · 78 pages · English
For other details of the current year results, refer to the Directors' Report - Review of Operations. 3. NTA backing Net tangible asset backing per ordinary security Reporting period Previous corresponding period 0.36 cents 0.72 cents 5. Audit This report is based on financial statements which have been audited. 6. Attachments Details of attachments (if any): The annual report for the year ended 3
Story so far
Earlier from Immutep
- French government research cash rebate of A$1.3M received
- Financial Update
- 2nd milestone payment to be received from Novartis
- Approvals received to initiate INSIGHT clinical trial
- Disclosure Under LR 3.10.5A and 7.1A.4(b)
Later from Immutep
- PRR & Monash Uni receive funding grant for LAG-3 Research
- Japanese Patent Grants For IMP321 In Infectious Disease
- Japanese Patent Grant for IMP731 Antibody
- European patent grant for IMP321 in cancer
- Immutep receives USD1M milestone payment from EOC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep